FdaApplication
NDA 204026
Identifiers
- fda_app_no: NDA204026
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2013-02-08 |
Revenue by product
POMALYST
| Period | Revenue |
|---|---|
| Q2 2026 | $204.0M |
| Q1 2026 | $513.0M |
| Q4 2025 | $692.0M |
| Q3 2025 | $675.0M |
| Q2 2025 | $708.0M |
| Q1 2025 | $658.0M |
| Q4 2024 | $823.0M |
| Q3 2024 | $898.0M |
| Q2 2024 | $959.0M |
| Q1 2024 | $865.0M |
| Q4 2023 | $890.0M |
| Q3 2023 | $872.0M |
| Q2 2023 | $847.0M |
| Q1 2023 | $832.0M |
| Q4 2022 | $877.0M |
| Q3 2022 | $886.0M |
| Q2 2022 | $908.0M |
| Q1 2022 | $826.0M |
| Q4 2021 | $854.0M |
| Q3 2021 | $851.0M |
| Q2 2021 | $854.0M |
| Q1 2021 | $773.0M |
| Q4 2020 | $835.0M |
| Q3 2020 | $777.0M |
| Q2 2020 | $745.0M |
| Q1 2020 | $713.0M |
| Q4 2019 | $322.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
| Q1 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| POMALYST | POMALIDOMIDE | 3MG | CAPSULE;ORAL |
| POMALYST | POMALIDOMIDE | 1MG | CAPSULE;ORAL |
| POMALYST | POMALIDOMIDE | 2MG | CAPSULE;ORAL |
| POMALYST | POMALIDOMIDE | 4MG | CAPSULE;ORAL |
4 products